JP2023527741A5 - - Google Patents
Info
- Publication number
- JP2023527741A5 JP2023527741A5 JP2022570279A JP2022570279A JP2023527741A5 JP 2023527741 A5 JP2023527741 A5 JP 2023527741A5 JP 2022570279 A JP2022570279 A JP 2022570279A JP 2022570279 A JP2022570279 A JP 2022570279A JP 2023527741 A5 JP2023527741 A5 JP 2023527741A5
- Authority
- JP
- Japan
- Prior art keywords
- unsubstituted
- substituted
- use according
- compound
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063027194P | 2020-05-19 | 2020-05-19 | |
| US63/027,194 | 2020-05-19 | ||
| PCT/US2021/032808 WO2021236543A1 (en) | 2020-05-19 | 2021-05-17 | Treatment for amyloidosis |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023527741A JP2023527741A (ja) | 2023-06-30 |
| JP2023527741A5 true JP2023527741A5 (enExample) | 2024-05-23 |
Family
ID=78708017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022570279A Pending JP2023527741A (ja) | 2020-05-19 | 2021-05-17 | アミロイドーシスの治療 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US20230210846A1 (enExample) |
| EP (1) | EP4138837A4 (enExample) |
| JP (1) | JP2023527741A (enExample) |
| KR (1) | KR20230013102A (enExample) |
| CN (1) | CN116133661A (enExample) |
| AU (1) | AU2021273731A1 (enExample) |
| BR (1) | BR112022023486A2 (enExample) |
| CA (1) | CA3183746A1 (enExample) |
| IL (1) | IL298297A (enExample) |
| MX (1) | MX2022014468A (enExample) |
| TW (1) | TW202207931A (enExample) |
| WO (1) | WO2021236543A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024546584A (ja) * | 2021-12-15 | 2024-12-26 | リキュリウム アイピー ホールディングス リミテッド ライアビリティー カンパニー | Ｂｃｌ－２阻害剤、ｗｅｅ－１阻害剤及び他の化学療法剤の三剤療法の組み合わせ |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3087261A1 (en) * | 2018-01-10 | 2019-07-18 | Recurium Ip Holdings, Llc | Benzamide compounds |
| US20210154368A1 (en) * | 2018-04-09 | 2021-05-27 | Case Western Reserve University | Bioink and crosslinkable support medium for printing |
| DK3774591T3 (da) * | 2018-04-10 | 2023-03-20 | Ddp Specialty Electronic Materials Us Llc | Dispenser til dåse med fast ventilspindelhus |
| US10511808B2 (en) * | 2018-04-10 | 2019-12-17 | Facebook, Inc. | Automated cinematic decisions based on descriptive models |
-
2021
- 2021-05-17 AU AU2021273731A patent/AU2021273731A1/en not_active Abandoned
- 2021-05-17 JP JP2022570279A patent/JP2023527741A/ja active Pending
- 2021-05-17 IL IL298297A patent/IL298297A/en unknown
- 2021-05-17 CA CA3183746A patent/CA3183746A1/en active Pending
- 2021-05-17 WO PCT/US2021/032808 patent/WO2021236543A1/en not_active Ceased
- 2021-05-17 CN CN202180060027.8A patent/CN116133661A/zh active Pending
- 2021-05-17 MX MX2022014468A patent/MX2022014468A/es unknown
- 2021-05-17 KR KR1020227044559A patent/KR20230013102A/ko not_active Withdrawn
- 2021-05-17 BR BR112022023486A patent/BR112022023486A2/pt not_active Application Discontinuation
- 2021-05-17 EP EP21807581.0A patent/EP4138837A4/en active Pending
- 2021-05-17 US US17/998,920 patent/US20230210846A1/en not_active Abandoned
- 2021-05-19 TW TW110118106A patent/TW202207931A/zh unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2012532889A5 (enExample) | ||
| RU2385721C2 (ru) | Комбинации, включающие антимускариновые агенты и кортикостероиды | |
| ES2657907T3 (es) | Aplicaciones terapéuticas de ectoína | |
| JP2012528792A5 (enExample) | ||
| JP6175364B2 (ja) | 子宮内膜増殖を抑制するための組成物および方法 | |
| MA39155A1 (fr) | Composition de solution d'aérosol stable, mise sous pression, de combinaison de bromure de glycopyrronium et de formotérol | |
| PE20241067A1 (es) | Composiciones, metodos y sistemas para la administracion de farmacos en aerosol | |
| US10456390B2 (en) | Combinations comprising MABA compounds and corticosteroids | |
| RU2018103940A (ru) | Фармацевтические композиции, содержащие антагонист интегрина альфа4, для применения в лечении воспалительных состояний глаза | |
| HRP20180944T1 (hr) | Stabilan pripravak stlačene aerosolne otopine kombinacije glikopironijeva bromida i formoterola | |
| BG107625A (bg) | Контрацептивен метод и форми за осъществяването му | |
| JP2006502160A5 (enExample) | ||
| US5407926A (en) | Ophthalmic composition | |
| SI2393477T1 (en) | Use of a glucocorticoid composition for the treatment of severe and uncontrolled asthma | |
| ES2247959T1 (es) | Formulacion medica en aerosol estabilizada en agua. | |
| NZ574658A (en) | Combination of azelastine and steroids such as fluticasone and mometasone for nasal and ocular use | |
| WO2014131852A1 (en) | Combinations comprising maba compounds and corticosteroids | |
| JP2020529418A5 (ja) | Ｔ細胞急性リンパ芽球性白血病を治療するための化合物、組成物及び方法 | |
| JP2021534201A5 (enExample) | ||
| JP2010502736A5 (enExample) | ||
| RU2005129276A (ru) | Применение стероидов для лечения субъектов, страдающих заболеванием глаз | |
| MXPA06013850A (es) | Combinaciones que comprenden agentes antimuscarinicos y corticosteroides. | |
| Bircher et al. | Contact Hypersensitivity to Corticosteroids in Routine Patch Test Patients: A Multi-Centre Study of the Swiss Contact Dermatitis Research Group | |
| IL312515A (en) | Bispecific cd16a binders | |
| AR089839A1 (es) | Composicion farmaceutica que combina cloruro de dietil-[6-(4-hidroxicarbamoil-fenil-carbamoiloxi-metil)-naftalen-2-il-metil]-amonio y al menos un agente activo antiinflamatorio para su uso en tratamiento de distrofia muscular |